莊皇集團公司(08501.HK)擬255萬港元收購譽榮財資全部股權
格隆匯2月14日丨莊皇集團公司(08501.HK)公佈,於2020年2月14日,買方Morrice Company Limited(乃公司全資附屬公司)與賣方陳思敏女士及邵滿元先生訂立一份有關收購事項之協議,買方擬收購目標公司譽榮財資有限公司全部股權及股東貸款,代價255萬港元。
目標公司乃一間於2015年7月23日在香港註冊成立的有限責任公司,主要於香港從事放債業務。目標公司根據放債人條例(香港法例第163章)持有放債人牌照。
董事認為簽署協議及其項下的收購事項為該集團提供機會以開展放債業務使該集團現有業務多元化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.